OverviewSuggest Edit

Recro Pharma is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam.

TypePublic
Founded2006
HQMalvern, US
Websiterecropharma.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Dec 2018)255
Job Openings9
Revenue (FY, 2018)$77.3 M(+8%)
Share Price (Jun 2019)$9.1 (-2%)

Key People/Management at Recro Pharma

Gerri Henwood

Gerri Henwood

President & Chief Executive Officer
Michael Celano

Michael Celano

COO
Ryan D. Lake

Ryan D. Lake

CFO
Stewart McCallum

Stewart McCallum

Chief Medical Officer
Fred Graff

Fred Graff

Chief Commercial Officer
Randy Mack

Randy Mack

Senior Vice President, Development
Show more

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd
Show all (1)

Recro Pharma Financials and Metrics

Recro Pharma Revenue

Recro Pharma's revenue was reported to be $77.35 m in FY, 2018
USD

Revenue (Q1, 2019)

25.1m

Gross profit (Q1, 2019)

10.7m

Gross profit margin (Q1, 2019), %

42.6%

Net income (Q1, 2019)

(2.0m)

EBIT (Q1, 2019)

1.7m

Market capitalization (10-Jun-2019)

201.4m

Closing stock price (10-Jun-2019)

9.1

Cash (31-Mar-2019)

46.0m

EV

261.4m
Recro Pharma's current market capitalization is $201.4 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

52.0m69.3m71.8m77.3m

Revenue growth, %

33%

Cost of goods sold

28.1m37.2m38.2m43.2m

Gross profit

23.9m32.2m33.6m34.2m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

18.7m16.5m17.7m17.3m17.0m18.7m16.9m17.1m19.5m21.7m18.3m25.1m

Cost of goods sold

9.4m10.0m10.3m9.5m5.7m10.5m10.4m6.9m10.5m12.1m8.5m14.4m

Gross profit

9.3m6.5m7.5m7.7m11.2m8.2m6.5m10.2m9.1m9.7m9.8m10.7m

Gross profit Margin, %

50%39%42%45%66%44%38%60%46%44%54%43%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

19.7m19.8m64.5m61.0m38.5m

Accounts Receivable

89.6k8.6m10.4m9.7m12.9m

Inventories

9.0m1.1m9.8m10.7m

Current Assets

20.4m38.7m84.8m87.3m71.1m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

29.9m27.8m23.9m16.6m15.7m28.3m14.9m14.8m24.8m19.5m8.7m11.8m46.3m48.9m35.8m46.0m

Accounts Receivable

35.8k86.8k80.2k15.0m9.6m12.2m11.5m12.4m12.3m10.1m13.1m9.8m11.7m11.7m16.2m

Inventories

9.6m8.6m7.6m6.7m9.8m7.8m6.9m9.9m10.0m8.1m10.2m10.2m

Current Assets

30.2m28.1m24.1m17.3m42.4m48.4m36.2m35.2m49.0m77.3m69.8m67.1m79.3m79.0m69.7m94.6m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(16.1m)3.0m(30.2m)(50.1m)(79.7m)

Depreciation and Amortization

1.4k4.1m5.0m4.9m5.3m

Inventories

1.3m(325.0k)(1.1m)(860.0k)

Accounts Payable

1.1m2.2m8.5m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(5.1m)(7.9m)(12.7m)(4.1m)(5.4m)(7.6m)(6.5m)(14.4m)(19.8m)(8.1m)(16.9m)(26.0m)(12.5m)(25.2m)(38.4m)(2.0m)

Depreciation and Amortization

1.3m2.7m1.3m2.5m3.8m1.2m2.4m3.7m1.2m2.5m3.8m1.4m

Inventories

345.0k1.4m1.3m2.3m(830.0k)936.0k1.9m(1.1m)(189.0k)1.7m(343.0k)531.0k

Accounts Payable

306.9k988.5k1.6m532.7k4.0m2.7m2.6m1.9m4.5m(2.4m)
USDY, 2019

EV/EBIT

158.4 x

EV/CFO

-20.9 x

Financial Leverage

-9.5 x
Show all financial metrics

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13
Show all operating metrics

Recro Pharma Revenue Breakdown

Embed Graph

Recro Pharma revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

Recro Pharma News and Updates

Recro Pharma Reports First Quarter 2019 Financial Results

Company to Host Conference Call Today at 8:00 AM ET Company to Host Conference Call Today at 8:00 AM ET

Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam

Management to Host Conference Call and Webcast Today at 4:30 p.m. ET Management to Host Conference Call and Webcast Today at 4:30 p.m. ET

Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

March 24, 2019 PDUFA Goal Date for IV Meloxicam

Recro Pharma Amends IV Meloxicam License Agreement with Alkermes

Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years Reduces 2019 Cash Requirements by $30 Million; Extends Approval Milestone Payments Over Seven Years

Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia

MALVERN, Pa., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the publication of previously reported Phase II clinical data for intraven…

Recro Pharma Reports Third Quarter 2018 Financial Results Raising Guidance for CDMO business for 2018

Company to Host Conference Call Today at 8:00 AM ET
Show more

Recro Pharma Blogs

Recro Pharma to Present at Upcoming Investor Conferences

MALVERN, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a pharma company with a high-performing, revenue generating contract development and manufacturing (CDMO) segment and an Acute Care segment, today announced that Gerri Henwood, the Company’s President and Chief Execu…

Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019

Conference Call and Webcast Scheduled for Friday, May 10, 2019 at 8:00 a.m. ET MALVERN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report first quarter financial results on Friday, May 10, 2019. Recro's management team will host a conferen…

Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville

Company Continues Important, Strategic Relationship with Key Global Customer; Long-Term Contract Executed Teva to Continue to be Exclusive Marketing Partner of Verapamil SR® Capsules with Same Revenue Economics as the Original Agreement MALVERN, Pa., April 16, 2019 (GLOBE NEWSWIRE) -- Recro Ph…

Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting

New Meta-Analysis Data Suggests IV Meloxicam Produces Largest SPID, Greater Reduction in Opioid Use and Better Safety Profile Compared to Other Non-Opioid Medications for Moderate to Severe Pain Abstract Among the Highest Scoring Presentations at the Meeting MALVERN, Pa., April 11, 2019 (GLOBE…

Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance

Implements Plan to Reduce Acute Care Segment Staff CDMO Segment Continues Strong Performance; Company Increases Revenue, Operating Income and EBITDA, as Adjusted* Guidance for 2019 Expects to Become Cash Flow Breakeven During Q3; Cash Flow Positive Second Half of 2019 Plans to Seek Strategic Pa…

Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors

MALVERN, Pa., March 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced the appointment of Arnaud Ajdler to the Company’s Board of Directors. Mr. A…
Show more

Recro Pharma Frequently Asked Questions

  • When was Recro Pharma founded?

    Recro Pharma was founded in 2006.

  • Who are Recro Pharma key executives?

    Recro Pharma's key executives are Gerri Henwood, Michael Celano and Ryan D. Lake.

  • How many employees does Recro Pharma have?

    Recro Pharma has 255 employees.

  • What is Recro Pharma revenue?

    Latest Recro Pharma annual revenue is $77.3 m.

  • What is Recro Pharma revenue per employee?

    Latest Recro Pharma revenue per employee is $303.3 k.

  • Who are Recro Pharma competitors?

    Competitors of Recro Pharma include Array BioPharma, Amicus Therapeutics and Durect.

  • Where is Recro Pharma headquarters?

    Recro Pharma headquarters is located at 490 Lapp Rd, Malvern.

  • Where are Recro Pharma offices?

    Recro Pharma has an office in Malvern.

  • How many offices does Recro Pharma have?

    Recro Pharma has 1 office.